Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
1. Cogent announced a $150 million public stock offering. 2. Additional $22.5 million option for underwriters to purchase shares. 3. Proceeds will fund development of bezuclastinib and working capital. 4. Offering's completion is subject to market conditions and regulatory approval. 5. Bezuclastinib targets specific mutations in serious diseases like systemic mastocytosis.